New diabetes treatment launched in the UK

A new diabetes treatment has been launched in the UK. Xultophy (insulin degludec/liraglutide; IDegLira), is the first ever treatment combining two existing treatments, long acting (basal) insulin (insulin degludec, Tresiba) and GLP-1 receptor agonist (liraglutide, Victoza) in one pen. Xultophy is indicated for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycaemic control. Adults with type 2 diabetes taking once-daily Xultophy had a significant improvement in blood sugar (measured by HbA1c). Additionally, Xultophy was shown to have a secondary benefit of weight loss and